Evolent Health, Inc (NYSE:EVH) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Analysts have rated Evolent Health, Inc (NYSE:EVH) with a consensus recommendation of "Buy", with one hold and twelve buy ratings reported among fourteen ratings firms.
• The average 12-month price target for Evolent Health set by analysts is $17.21, with individual targets ranging from $9.00 to $20.00.
• Evolent Health reported a significant decrease in revenue, down 31.3% year-over-year, and posted a loss of ($0.10) EPS for the most recent quarter, missing analyst estimates by $0.20.

Shares of Evolent Health, Inc (NYSE:EVH - Get Free Report) have been given a consensus rating of "Buy" by the fourteen ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $17.2143.

EVH has been the topic of several analyst reports. Canaccord Genuity Group reaffirmed a "buy" rating and set a $16.00 target price on shares of Evolent Health in a report on Tuesday, September 9th. Truist Financial upped their price target on shares of Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Stephens reaffirmed an "equal weight" rating and issued a $9.00 price target on shares of Evolent Health in a research note on Wednesday. BTIG Research reissued a "buy" rating and issued a $20.00 price objective on shares of Evolent Health in a research note on Tuesday, September 9th. Finally, Piper Sandler lifted their target price on shares of Evolent Health from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th.

Institutional Trading of Evolent Health

A number of hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its position in shares of Evolent Health by 88.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company's stock valued at $29,000 after purchasing an additional 1,194 shares in the last quarter. Banque Cantonale Vaudoise acquired a new stake in shares of Evolent Health in the 1st quarter worth $25,000. Parallel Advisors LLC raised its holdings in shares of Evolent Health by 82.6% during the 2nd quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company's stock worth $39,000 after acquiring an additional 1,577 shares during the period. Strs Ohio acquired a new position in shares of Evolent Health during the 1st quarter valued at about $47,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Evolent Health in the second quarter valued at about $58,000.

Evolent Health Price Performance

NYSE EVH opened at $8.96 on Friday. The stock's fifty day moving average price is $9.33 and its 200 day moving average price is $9.48. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.01 and a quick ratio of 1.01. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -5.57 and a beta of 0.73. Evolent Health has a 1 year low of $7.06 and a 1 year high of $29.58.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The firm had revenue of $444.33 million for the quarter, compared to analyst estimates of $459.43 million. During the same period last year, the firm earned $0.30 EPS. The company's revenue for the quarter was down 31.3% compared to the same quarter last year. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts forecast that Evolent Health will post 0.08 earnings per share for the current year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.